NICE has published new standards setting out the requirements needed to develop digital health technologies for the NHS and speed up uptake of products like healthcare apps and wearable devices.
NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for m
The UK government has reached a new five-year medicines pricing deal with the pharma industry to replace the almost 60-year-old Pharmaceutical Price Regulation Scheme (PPRS).
NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.